Although tGC are currently the first-line treatment of choice in inflammatory skin conditions (19), PIM has a more specific anti-inflammatory and immunosuppressive mechanism of action, exerting an effect on T lymphocytes and mast cells and thus minimizing skin atrophy (20, 21). The gene discussed is TGM2; the disease is skin atrophy.